10x Genomics Inc. stocks have been trading up by 13.01 percent following strong demand for its advanced single-cell sequencing platforms.
Click Here for a Millionaire's POV on Trading TXG
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For TXG Traders
- A Delaware jury validated three 10x Genomics patents, awarding over $4.8M in damages and opening the door to enhanced damages, fees, and a possible U.S. injunction against Qiagen’s Parse unit.
- A new Lunit AI pathology partnership plugs Lunit SCOPE IO into TXG’s Xenium and Atera platforms, tightening the company’s grip on oncology biomarker discovery workflows.
- RBC started coverage at Sector Perform with a $70 target, flagging TXG’s leading spatial profiling share but warning that single‑cell growth looks flat for the next five years.
- Deutsche Bank lifted its TXG target to $70 from $40, while the ticker still sits around a $52 consensus target and an average Overweight rating.
- Recent Form 4 filings show sizable insider sales by TXG’s CFO and a director, though both continue to hold large Class A positions.
Live Update At 16:46:57 EDT: On Thursday, September 24, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 13.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TXG has been trading like a momentum rollercoaster. Over the last few weeks, 10x Genomics has ripped from a late‑August close near $62 to about $84 on 2026/09/24. That’s a strong multi‑week trend, backed by clear buying pressure on the daily chart.
The intraday tape on 2026/09/24 shows TXG opening near $75.5, then grinding higher all day and closing at $84.11, with late‑day pushes into the mid‑$85s. For active traders, that’s classic trend‑day behavior: higher lows, steady bids, and no real breakdown attempts holding.
More Breaking News
- Accenture Stock Rallies As AI Deals And Targets Climb
- MEDS Stock Rockets As Helomics Deal And GLP‑1 App Ignite Trading
- IBRX Stock Holds Gains As Soon‑Shiong Expands Oncology Network
- CNTB Stock Slides Toward $1 As Biotech Traders Refocus
Under the hood, TXG is still a growth‑story name, not a profit machine. Revenue over the last year sits around $643M, with gross margin near 70%, but operating margins are negative and the latest quarter printed a net loss of about $17.9M. The company is burning earnings but generating positive operating cash flow of roughly $17M last quarter and free cash flow near $15.4M. A current ratio of 5.7 and low debt (total debt‑to‑equity ~0.1) give TXG room to keep spending on R&D and product launches, which matters for a premium‑valued tools stock trading around 17x sales.
Why Traders Are Watching TXG Now
TXG is in the middle of a high‑stakes pivot from being “just” the single‑cell leader to becoming a full‑stack spatial biology and oncology insights platform. The Lunit deal is the cleanest example. By tying Korea‑based Lunit’s AI pathology engine (Lunit SCOPE IO) into Xenium and Atera, 10x Genomics gives labs a way to read basic H&E slides and rich spatial molecular data in one workflow. For oncology research, especially antibody‑drug conjugates and immunotherapy response, that is exactly where the science is headed.
For traders, the key point is not near‑term revenue — those numbers were not disclosed. It is positioning. TXG is wiring itself into the decision‑making layer of cancer drug development. That kind of sticky, high‑value role often supports premium multiples, which TXG already enjoys.
On the legal side, the Delaware jury verdict against Qiagen’s Parse Biosciences unit matters beyond the $4.8M check. The court confirmed three Scale Biosciences patents as valid and infringed, with damages tied to a 14% royalty on Evercode Whole Transcriptome sales from 2021 to mid‑2026. TXG plans to chase enhanced damages, attorneys’ fees, and a possible U.S. injunction. That tells you management is ready to defend its turf aggressively in single‑cell analysis.
Yet when that verdict hit, TXG traded down about 5% in a weak biotech tape. That disconnect is a classic reminder: broader sector flows can overpower stock‑specific wins in the short term. Traders who only look at headlines, not the chart and volume, miss that nuance.
Layer in the Street’s view: RBC and Deutsche Bank both sit at a $70 target, while UBS is Neutral at $68 and the average target is roughly $52. TXG gets credit for owning more than 60% share in spatial profiling and delivering double‑digit growth. But the same reports warn that single‑cell revenue is likely to be flat over the next five years thanks to pricing pressure and market maturity. That tension — spatial strength versus single‑cell slowdown — is what’s driving debate around TXG’s next big move.
Insider activity adds another wrinkle. CFO Adam Taich sold about $3.0M of stock and still holds over 316,000 shares. Director John Stuelpnagel sold roughly $1.24M but keeps more than 328,000 shares. Traders will see the sales as a mild yellow flag, yet the remaining stakes show they still have plenty of skin in the game.
Conclusion
Right now, TXG sits at the crossroads of strong momentum, rich valuation, and real strategic change. The tape shows buyers in control, with the stock breaking out from the low‑$60s to the mid‑$80s in a matter of weeks. The fundamentals show a cash‑rich, low‑debt company with 70% gross margins but negative earnings, paying up to defend patents and build new AI‑driven workflows.
The news flow around 10x Genomics is mixed but tradable. On one side, TXG is stacking long‑term positives: the Lunit AI pathology partnership, a solid patent win against Qiagen’s Parse unit, and a Street that is slowly nudging price targets higher into the $68–$70 range. On the other side, traders have to respect the drag from a mature single‑cell business, insider selling noise, and a sector that can flip risk‑off without warning.
For active traders who live by charts and catalysts, TXG is a name to study deeply, not chase blindly. As Tim Sykes likes to remind his students, “Trade the price action, not the hype.” And as Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” TXG’s story — from AI oncology tools to courtroom victories — is powerful, but the only thing that pays or punishes in real time is the chart. This article is for educational and research purposes only and is not investment advice; use it as a starting point for your own due diligence and risk management.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.